NCT05382637View on ClinicalTrials.gov

Growth Hormone in a Patient With a Dominant-Negative GHR Mutation

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

August 26, 2022

Primary Completion Date

September 1, 2023

Study Completion Date

September 1, 2028

Conditions
Growth Disorders
Interventions
DRUG

Somatropin

Daily growth hormone at a starting dose of 50 mcg/kg/day and escalating

Trial Locations (1)

20010

Children's National Hospital, Washington D.C.

Sponsors
All Listed Sponsors
lead

Children's National Research Institute

OTHER